WebMD are reporting:
Members do not see these Ads. Sign Up.Rivera, E. Journal of Alzheimer's Disease, November 2005; vol 7: pp 1-20. News release
Tags:
-
-
More on Alzheimer's
Couple of press releases on breakthroughs in the understanding of Alzheimers:
From Science Daily: -
Further link between diabetes and Alzheimer's
ScienceDaily are reporting:
Diabetes Drug Shows Promise In Treating Alzheimer's
-
Diabetes may be linked to Alzheimer's
CTV are also reporting:
Diabetes may be linked to Alzheimer's: studies
-
Red Wine Prevents Alzheimer's
Ivanhone Newswire are reporting:
Red Wine Prevents Alzheimer's
-
Press Release:
MayoClinic Highlights Possible Diabetes And Alzheimer's Connection -
Another new report on this:
Could Alzheimer’s be a Form of Diabetes?
(Ivanhoe Newswire) -- Could a new form of diabetes be to blame for the memory loss of Alzheimer’s disease?
-
Sugary Beverages May Increase Alzheimer's Risk
Excess drinking of sugary beverages like soda may increase the risk of Alzheimer's disease, suggests new research in mice. Although the exact mechanisms aren't known, obesity and diabetes are both associated with higher incidences of Alzheimer's.
More... -
ScienceDaily are reporting:
Diabetes Link To Alzheimer's Disease Explained
-
The pathological interaction between diabetes and presymptomatic Alzheimer's diseaseNeurobiology of Aging; Available online 26 March 2008
Joseph R. Burdo, Qi Chen, Nigel A. Calcutt, David Schubert
-
Science Daily are reporting:
Insulin Is A Possible New Treatment For Alzheimer's
-
Press Release:
UB Study Suggests That Insulin Could Be Potential Therapy for Alzheimer's Disease
-
Press Release:
Researchers Identify How a Gene Linked to Both Alzheimer’s Disease and Type 2 Diabetes Works
-
Amyloid-β and Tau Pathology of Alzheimer’s Disease Induced by Diabetes in an Animal Model
Claudine L. Bitel, Chinnaswamy Kasinathan, Rajesh H. Kaswala, William L Klein, Peter H. Frederikse
Journal of Alzheimer's (in press)
-
Press Release:
Diabetes Drug Could Help Fight Alzheimer's Disease
-
Here is an opinion piece in the New York Times about this:
Is Alzheimer’s Type 3 Diabetes? -
Press Release:
Salk study finds diabetes raises levels of proteins linked to Alzheimer's features
Mouse model may provide clues on mechanism linking diabetes and aging to Alzheimer's
-
Press Release:
Type II diabetes and the Alzheimer's connection
Scientists study interactions between two molecules thought to play critical roles in these diseases
-
Press Release:
Diabetes drug may reverse Alzheimer's and enters major clinical trial
-
Epigenetic mechanisms linking diabetes and synaptic impairments
Jun Wang et al
Diabetes October 23, 2013
-
Press Release:
Amyloid Formation May Link Alzheimer Disease and Type 2 Diabetes
Islet Amyloid Peptide Found in Human Brain Senile Plaques with Beta-Amyloid, According to Study Published in The American Journal of Pathology
-
News Release
Joslin Scientists Find Direct Link between Insulin Resistance in the Brain and Behavioral Disorders
Study in mice identifies mechanism that lowers levels of dopamine and heightens behavior suggesting anxiety and depression
-
Insulin Resistance in Alzheimer Disease: Is Heme Oxygenase-1 an Achille's Heel?
Barone E, Allan Butterfield D
Neurobiol Dis. 2015 Feb 27
-
Press Release:
Trinity researchers report major breakthrough in understanding Alzheimer's disease
-
An updated Meta-Analysis of cohort studies: diabetes and risk of Alzheimer’s disease
Jieyu Zhang et al
Diabetes Res Clin prac; Article in Press
-
PUBLIC RELEASE: 23-MAR-2017
Insulin resistance may lead to faster cognitive decline
Executive function and memory are particularly vulnerable to the effects of insulin resistance, Tel Aviv University researchers say
-
PUBLIC RELEASE: 7-AUG-2018
Alzheimer's disease and type 2 diabetes: Hope for inhibitors against amyloid plaques
Designed peptides as potential inhibitors of amyloid plaques
Effective therapeutics to counteract the formation of amyloid plaques in Alzheimer's disease and type 2 diabetes are not yet available. Scientists at the Technical University of Munich (TUM) have now come a little bit closer to a solution: They have described a new class of designed macrocyclic peptides that are highly potent inhibitors of amyloid formation.
Amyloid plaques, which are protein deposits, play a crucial role in the development of Alzheimer's disease and type 2 diabetes. Several teams of scientists around the world are working on finding ways to prevent amyloid plaque formation in the human brain.
The research team of Aphrodite Kapurniotu, Professor for Peptide Biochemistry (TUM) has been working on an idea for some time now in collaboration with the teams of Professor Martin Zacharias (TUM), Professor Gerhard Rammes (TUM Rechts der Isar Hospital) and Professor Jürgen Bernhagen (Institute for Stroke and Dementia Research (ISD) at Ludwig Maximilian University (LMU)). The researchers present now macrocyclic peptides (MCIPs) as potent inhibitors of amyloid formation; they reported their results in the journal Angewandte Chemie. The work has been supported by Deutsche Forschungsgemeinschaft (DFG) collaborative research center SFB 1035.
New class of amyloid inhibitors
In its new study, the team presents macrocyclic peptides, developed as a new class of amyloid inhibitors. "We have discovered an MCIP that is stable in human blood plasma and can also overcome the human blood-brain barrier in an in vitro cell culture model," explains Professor Kapurniotu. She adds: "So far we were 'only' able to demonstrate these properties in the test tube - thus further research is necessary. But these are two highly desirable properties for inhibitors of Alzheimer's amyloid."
TUM has already applied for a patent for the newly developed macrocyclic peptides. "They could be a good alternative to the currently pursued antibody-based approaches as therapeutics against Alzheimer's amyloid plaque formation because they are easy to produce, have promising properties and, due to their peptidic nature, they will be significantly cheaper than antibodies," says Professor Kapurniotu.
"Therefore, further investigations are now planned to verify whether the MCIPs are also effective in in vivo models. Furthermore, the MCIPs could also be suitable as templates for the development of small molecule peptidomimetics (molecules mimicking peptide chains), which might also find application as anti-amyloid drugs in Alzheimer's and type 2 diabetes. -
Cognitive dysfunction: A growing link between diabetes and Alzheimer's disease.
Jash K et al
Drug Dev Res. 2019 Aug 5
Loading...
- Similar Threads - Alzheimer's Form Diabetes
-
- Replies:
- 1
- Views:
- 6,092
-
- Replies:
- 4
- Views:
- 15,960
-
- Replies:
- 0
- Views:
- 192
-
- Replies:
- 1
- Views:
- 414
-
- Replies:
- 0
- Views:
- 215
-
- Replies:
- 0
- Views:
- 610
-
- Replies:
- 0
- Views:
- 694